The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study.
Ganghee ChaeAram ChoiSoyeoun LimSooneun ParkSeungjun LeeYoungick AhnJin Hyoung KimSeung Won RaYangjin JegalJongjoon AhnEun Ji ParkJaebum JunWoon Jung KwonTaehoon LeePublished in: Tropical medicine and infectious disease (2022)
In patients with severe COVID-19, clinical outcomes can be improved by administering regdanvimab, in addition to remdesivir.